The market environment currently balances a cautious Federal Reserve stance with intense scrutiny of AI-driven earnings growth. While AI demand remains robust, increased competition and financing concerns are driving greater dispersion in market reactions. Retail investor participation has cooled, with volumes down approximately 20% since June, leading to a shift in options market dynamics. Although call buying has waned, rising put activity reflects growing uncertainty heading into year-end. Credit markets show signs of stress, particularly in AI-exposed sectors, as issuance levels in 2026 significantly outpace previous years. Amidst this consolidation, biotech emerges as a compelling opportunity, offering secular growth potential supported by lower interest rates, increased M&A activity, and AI-accelerated drug discovery.
Sign in to continue reading, translating and more.
Open full episode in Podwise